Market Size of Global Sirolimus Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Sirolimus Market Analysis
The Sirolimus Market is expected to register a CAGR of 4.1% during the forecast period. Sirolimus also known as rapamycin is a macrolide antibiotic produced by Streptomyces hygroscopicus with potent immunosuppressive activity. It acts by impairing cytokine-induced lymphocyte proliferation. Sirolimus is primarily used as an immunosuppressant for patients undergoing organ transplantation, and can also be used as a chemotherapeutic agent.
The COVID-19 pandemic affected the healthcare industry significantly during the year 2020. However, data from the United Network for Organ Sharing (UNOS) published in 2021 states that there was not a huge decrease in organ transplant numbers during the pandemic which was majorly due to the dedication and collaboration of donor hospitals, organ procurement organizations, and transplant hospitals. As organ transplant is an essential procedure, it was performed at a regular pace during the pandemic. Hence, it is observed that the market for Sirolimus was not majorly hampered by the covid pandemic, however, few people have faced the troubles of acquiring hospital services due to the restriction on travel.
Sirolimus is unique from the other calcineurin inhibitors such as tacrolimus and cyclosporine, in its targeting of mTOR. The mammalian target of rapamycin (mTOR) coordinates cell growth and cell proliferation and its signaling pathway is implicated in the development of various conditions such as neurological diseases, cancer, genetic disorders, and obesity. As Sirolimus targets mTOR which involve in various critical biological functions, and it has many treatment applications beyond organ transplantation. Apart from organ transplantation application, this drug can be used in coating coronary stents for preventing rejection of transplanted organs by the body system and used for treating lymphangioleiomyomatosis, which is a rare lung ailment.
According to the World Health Organization (WHO), 2021 data suggest that the number of organ transplants is on the rise across the major countries in the world. This increasing transplantation rates and occurrence of lifestyle-related diseases, the promising pipeline for different indications, and improving healthcare infrastructure are the key driving factors of the sirolimus market.
